Edition:
United States

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

13.00USD
20 Jul 2018
Change (% chg)

$-0.22 (-1.66%)
Prev Close
$13.22
Open
$13.29
Day's High
$13.36
Day's Low
$12.97
Volume
238,695
Avg. Vol
381,812
52-wk High
$25.92
52-wk Low
$11.88

Latest Key Developments (Source: Significant Developments)

Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77
Thursday, 22 Feb 2018 04:05pm EST 

Feb 22 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL.Q4 GAAP EARNINGS PER SHARE $0.77.Q4 REVENUE ROSE 124 PERCENT TO $53.3 MILLION.SEES FY 2018 REVENUE $275 MILLION TO $300 MILLION.SEES FY 2017 REVENUE $159.2 MILLION.QUARTERLY NON-GAAP NET INCOME PER SHARE $0.19.Q4 EARNINGS PER SHARE VIEW $0.18, REVENUE VIEW $53.7 MILLION -- THOMSON REUTERS I/B/E/S.CORCEPT THERAPEUTICS - ‍ INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL SHOW NO EVIDENCE OF PROGESTERONE RECEPTOR AFFINITY; NO SERIOUS ADVERSE EVENTS​.‍ RELACORILANT TRIAL SHOWS STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS IN GLUCOSE TOLERANCE , SERUM OSTEOCALCIN​.  Full Article

Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77
Thursday, 22 Feb 2018 04:05pm EST 

Feb 22 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL.Q4 GAAP EARNINGS PER SHARE $0.77.Q4 REVENUE ROSE 124 PERCENT TO $53.3 MILLION.REPORTS 2017 REVENUE $159.2 MILLION.SEES FY 2018 REVENUE $275 MILLION TO $300 MILLION.QUARTERLY NON-GAAP NET INCOME PER SHARE $0.19.Q4 EARNINGS PER SHARE VIEW $0.18, REVENUE VIEW $53.7 MILLION -- THOMSON REUTERS I/B/E/S.CORCEPT THERAPEUTICS - ‍ INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL SHOW NO EVIDENCE OF PROGESTERONE RECEPTOR AFFINITY; NO SERIOUS ADVERSE EVENTS​.‍RELACORILANT TRIAL SHOWS STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS IN GLUCOSE TOLERANCE , SERUM OSTEOCALCIN​.  Full Article

Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application
Monday, 5 Feb 2018 08:50am EST 

Feb 5 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA.CORCEPT THERAPEUTICS - TEVA PHARMA USA SUBMITTED ANDA SEEKING AUTHORIZATION TO MANUFACTURE, USE, SELL GENERIC VERSION OF KORLYM MIFEPRISTONE TABLETS IN U.S..CORCEPT THERAPEUTICS SAYS NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY TEVA'S PROPOSED PRODUCT - SEC FILING.  Full Article

Corcept Therapeutics, Dohmen Entered Into Settlement Agreement And Mutual Release Of Any And All Claims That May Have Existed Between Parties
Wednesday, 17 Jan 2018 07:41am EST 

Jan 17 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS - CO, DOHMEN ENTERED INTO SETTLEMENT AGREEMENT AND MUTUAL RELEASE OF ANY AND ALL CLAIMS THAT MAY HAVE EXISTED BETWEEN PARTIES.CORCEPT THERAPEUTICS SAYS DOHMEN AGREED TO DELIVER TO CORCEPT ALL OF CASH DOHMEN COLLECTED FROM SALE OF KORLYM ON CORCEPT'S BEHALF - SEC FILING.CORCEPT THERAPEUTICS INC - ‍TOTAL AMOUNT DELIVERED BY DOHMEN TO CORCEPT UNDER SETTLEMENT AGREEMENT WAS $12.9 MILLION - SEC FILING.  Full Article

Corcept Therapeutics posts Q3 earnings per share $0.11
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q3 GAAP earnings per share $0.11.Q3 revenue $42.8 million versus I/B/E/S view $42 million.Q3 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $157 million to $162 million.  Full Article

Corcept Therapeutic says Dohmen Life Science Services filed a complaint alleging Corcept unlawfully terminated Dohmen agreement
Wednesday, 30 Aug 2017 09:09am EDT 

Aug 30 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics Inc - On August 7, 2017, Dohmen Life Science Services filed a complaint alleging corcept unlawfully terminated dohmen agreement.Corcept Therapeutics - Dohmen has since informed Corcept that it is withholding cash payments it collects from sale of Korlym that Dohmen is obligated to pay.Corcept Therapeutics Inc - These cash and receivables total approximately $13.2 million..Corcept Therapeutics Inc - Dohmen has stated that it will remit to Corcept any balance in excess of its calculation of such damages..Corcept Therapeutics - On August 29, corcept filed complaint against Dohmen alleging fraudulent inducement, negligent misrepresentation, breach of contract.Corcept Therapeutics - Immediately following Dohmen's cessation of services under agreement, Corcept began serving Korlym patients through another specialty pharmacy.  Full Article

Corcept Therapeutics says entered into distribution services agreement with Optime Care to provide specialty pharmacy services to co- SEC Filing‍​
Monday, 7 Aug 2017 06:01pm EDT 

Aug 7 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics - on Aug 4, co entered into distribution services agreement with Optime Care to provide specialty pharmacy services to co ‍​.Corcept Therapeutics-under terms of agreement Optime will act as exclusive specialty pharmacy distributor of Korlym in us for term of agreement.Corcept Therapeutics says ‍initial term of agreement is 5 yrs from effective date of Aug 4, unless earlier terminated pursuant its terms - SEC filing​.  Full Article

Corcept Therapeutics Q2 GAAP earnings per share $0.10
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces second quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q2 non-GAAP earnings per share $0.13.Q2 GAAP earnings per share $0.10.Q2 revenue $35.6 million versus I/B/E/S view $32.5 million.Sees FY 2017 revenue $145 million to $155 million.Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.FY2017 revenue view $131.9 million -- Thomson Reuters I/B/E/S.  Full Article

Corcept therapeutics Q1 GAAP earnings per share $0.04
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces first quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q1 non-GAAP earnings per share $0.06.Q1 GAAP earnings per share $0.04.Q1 revenue $27.6 million versus I/B/E/S view $25.5 million.Sees FY 2017 revenue $125 million to $135 million.Q1 earnings per share view $0.03 -- Thomson Reuters I/B/E/S.FY2017 revenue view $124.0 million -- Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics files for mixed shelf of up to $200 mln
Monday, 13 Mar 2017 05:12pm EDT 

Corcept Therapeutics Inc : Files for mixed shelf of up to $200 million - SEC filing . In addition, 349,425 shares of co's common stock offered by the selling stockholders . Co will not receive any proceeds from the sale of co's common stock by the selling stockholders Source: (http://bit.ly/2nxNmIM) Further company coverage: [CORT.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Corcept Therapeutics Reports Qtrly Revenue $57.7 Million

* CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE